Bolder BioTechnology, Inc. today announced that it has been awarded a $1.9 million Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of The National Institutes of Health (NIH). The grant will be used to perform additional preclinical toxicology and pharmacology studies of the company’s proprietary
Full Post: Bolder BioTechnology awarded NIH grant to continue development of growth hormone product
With a pre-emptive, prophylactic skin regimen, patients who receive panitumumab for treatment of metastatic colorectal cancer may be able to avoid some of the skin-associated toxicities, according to data presented at the 2009 American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco.
Edith Mitchell, M.D., a clinical professor in the Department of Medical Oncology at Jefferson Medical College of Thomas Jefferson University, presented data from the study, which was the first prospective study to compare pre-emptive and reactive skin treatment for skin toxicities related to panitumumab. The study was co-led by Dr. Mitchell and Mario Lacouture, M.D., an assistant professor of Dermatology at Northwestern University’s Feinberg School of Medicine in Chicago.
Skin toxicities are the most common adverse effects related to panitumumab (Vectibix), which is a fully human monoclonal antibody that targets the epidermal growth factor receptor (EGFR). The toxicities could include erythema, dermatitis, pruritus, pustules, rash, and hair and nail changes.
“Panitumumab and the other EGFR inhibitors are now key components to the treatment strategies for metastatic colorectal cancer,” Dr. Mitchell said. “But the majority of the patients who receive these agents suffer from skin toxicities, and for some patients, the treatment must be interrupted or discontinued. If we can prevent or minimize these toxicities, it would be a significant advance in patient care.”
The researchers studied 95 patients receiving panitumumab in combination with irinotecan-based chemotherapy. The patients were randomized to receive pre-emptive skin toxicity treatment initiated 24 hours prior to the first dose of panitumumab, then given daily through week six, or reactive skin treatment after the skin toxicity developed. The skin treatment included moisturizers, sunscreen, topical steroids and oral doxycycline.
The primary endpoint was the incidence of specific grade 2 or higher skin toxicities during the six week skin treatment period. The incidence of these toxicities was reduced more than 50% in the group that received pre-emptive treatment.
Quality of life was also assessed, using the Dermatology Life Quality Index. Patients who received the pre-emptive, prophylactic skin treatment regimen reported an improved quality of life, even around week three, which was the median time to first grade 2 or higher skin toxicity in the reactive skin treatment group.
“This study supports the notion that, as with other side effects to cancer treatments, it is more advantageous to treat prophylactically, than to wait for the side effect to fully develop,” Dr. Lacouture said. “Futhermore, it shows that treating early on does not affect the benefit received from the anticancer therapy.”
http://www.jefferson.edu/
--------------------------------------------------------------------------------------------
Related Posts:
Patients with locally advanced lung cancer who receive chemotherapy and proton therapy, a specialized form a radiation therapy only available in a few centers in the United States, have fewer instances of a serious side effect called bone marrow toxicity than patients who receive chemotherapy and another type of radiation therapy called intensity modulated radiation
Full Post: Proton therapy may reduce serious side effect of lung cancer treatment
Biothera has announced today it began dosing patients in the second arm of its metastatic colorectal cancer (mCRC) trial in August. This arm of the trial is evaluating the combination therapy of its lead drug candidate, Imprime PGG, with Erbitux, an anti-cancer monoclonal antibody from ImClone Systems. Unlike the first trial arm, the second treatment
Full Post: Biothera initiates second phase of metastatic colorectal cancer trial
Results from a Phase 3 study show that patients with metastatic breast cancer who were treated previously with an anthracycline in the adjuvant setting experienced a significant improvement in time to disease progression (TTP) and overall response rates after receiving a combination of Doxil (doxorubicin HCl liposome injection) and docetaxel as compared to docetaxel alone.
Full Post: Doxil and docetaxel combination treatment delays disease progression in metastatic breast cancer
An enzyme that is overexpressed in pancreatic cancer cells may hold the key to successfully treating the disease with targeted immunotherapy, researchers from Thomas Jefferson University reported at the 2008 Annual Meeting of the Southern Surgical Association. Previous data show that a protein, indoleamine 2,3-dioxygenase (IDO), is overexpressed in pancreatic ductal adenocarcinomas, according to Jonathan
Full Post: Protein indoleamine 2,3-dioxygenase points to new pancreatic cancer therapies
A former Sydney skin cancer doctor who may have jeopardised the health of thousands of his former patients is apparently planning to appeal against his deregistration. Following a Health Department investigation which revealed serious concerns about the treatment of some of David Lindsay’s patients received at the Mid-City Skin Cancer Centre in George Street, in
Full Post: Deregistered cancer doctor in denial about risking 6,770 lives --------------------------------------------------------------------------------------------
